NAT2 acetylator
Selected indexed studies
- NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis. (Pharmacogenet Genomics, 2018) [PMID:29781872]
- The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis. (Sci Rep, 2020) [PMID:32107440]
- NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population. (Pharmacogenomics, 2019) [PMID:31699005]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis. (2018) pubmed
- The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis. (2020) pubmed
- NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population. (2019) pubmed
- NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study. (2025) pubmed
- Differential distribution of NAT2 polymorphisms and NAT2 acetylator phenotypes among indigenous populations of the Brazilian Amazon. (2024) pubmed
- Genotype-Guided Hydralazine Therapy. (2020) pubmed
- NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients. (2016) pubmed
- NAT2 rapid acetylator phenotype and increased risk of tuberculosis retreatment: A TB cohort study in Northern Thailand. (2025) pubmed
- Haplotype-specific PCR for NAT2 diplotyping. (2020) pubmed
- 4-Aminobiphenyl downregulation of NAT2 acetylator genotype-dependent N- and O-acetylation of aromatic and heterocyclic amine carcinogens in primary mammary epithelial cell cultures from rapid and slow acetylator rats. (2009) pubmed